This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IVERIC bio Dirección

Dirección controles de criterios 2/4

El CEO de IVERIC bio es Glenn Sblendorio , nombrado en Jul 2017, tiene una permanencia de 6.17 años. compensación anual total es $9.82M, compuesta por 7.1% salario y 92.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.17% de las acciones de la empresa, por valor de €8.69M. La antigüedad media del equipo directivo y de la junta directiva es de 5.5 años y 4.6 años, respectivamente.

Información clave

Glenn Sblendorio

Chief Executive Officer (CEO)

US$9.8m

Compensación total

Porcentaje del salario del CEO	7.1%
Permanencia del CEO	6yrs
Participación del CEO	0.2%
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Glenn Sblendorio en comparación con los beneficios de IVERIC bio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2023	n/a	n/a	-US$223m
Dec 31 2022	US$10m	US$700k	-US$185m
Sep 30 2022	n/a	n/a	-US$159m
Jun 30 2022	n/a	n/a	-US$141m
Mar 31 2022	n/a	n/a	-US$122m
Dec 31 2021	US$6m	US$665k	-US$115m
Sep 30 2021	n/a	n/a	-US$107m
Jun 30 2021	n/a	n/a	-US$108m
Mar 31 2021	n/a	n/a	-US$96m
Dec 31 2020	US$4m	US$640k	-US$85m
Sep 30 2020	n/a	n/a	-US$77m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$2m	US$599k	-US$59m
Sep 30 2019	n/a	n/a	US$63m
Jun 30 2019	n/a	n/a	US$62m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$1m	US$625k	US$63m
Sep 30 2018	n/a	n/a	-US$51m
Jun 30 2018	n/a	n/a	US$153m
Mar 31 2018	n/a	n/a	US$144m
Dec 31 2017	US$3m	US$560k	US$114m
Sep 30 2017	n/a	n/a	US$57m
Jun 30 2017	n/a	n/a	-US$192m
Mar 31 2017	n/a	n/a	-US$200m
Dec 31 2016	US$9m	US$373k	-US$193m

Compensación vs. Mercado: La compensación total de Glenn($USD9.82M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.59M).

Compensación vs. Ingresos: La compensación de Glenn ha aumentado mientras la empresa no es rentable.

CEO

Glenn Sblendorio (67 yo)

6yrs

Permanencia

US$9,816,150

Compensación

Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Glenn Sblendorio	CEO & Director	6yrs	US$9.82m	0.17% € 8.7m
Pravin Dugel	President & Director	2.2yrs	US$4.63m	0.15% € 7.4m
David Carroll	Senior VP	6.3yrs	US$2.68m	0.032% € 1.6m
Keith Westby	Senior VP & COO	6.5yrs	US$2.66m	0.029% € 1.4m
Christopher Simms	Senior VP & Chief Commercial Officer	1.9yrs	US$2.67m	0.024% € 1.2m
Samir Patel	Co-Founder and Consultant	16.5yrs	sin datos	sin datos
Xiao-Ping Dai	Chief Technical Officer	2.5yrs	sin datos	sin datos
Kathy Galante	Senior VP of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Todd Anderman	Senior VP	5.4yrs	sin datos	sin datos
Amy Sheehan	Senior VP & Chief Human Resources Officer	5.5yrs	sin datos	sin datos
Evelyn Harrison	Senior VP & Chief Clinical Operations Officer	7.5yrs	US$411.67k	sin datos
Guangping Gao	Chief Strategist of Gene Therapy	3.7yrs	sin datos	sin datos

5.5yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de O2T es experimentado (5.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Glenn Sblendorio	CEO & Director	6.2yrs	US$9.82m	0.17% € 8.7m
Pravin Dugel	President & Director	less than a year	US$4.63m	0.15% € 7.4m
Axel Bolte	Independent Director	15.9yrs	US$354.59k	0.016% € 801.9k
Adrienne Graves	Independent Chairman of the Board	4.6yrs	US$398.34k	0.016% € 801.9k
Mark Blumenkranz	Independent Director	3yrs	US$354.59k	0.023% € 1.2m
Carl Regillo	Member of Scientific Advisory Board	no data	sin datos	sin datos
Calvin Roberts	Independent Director	4.5yrs	US$365.84k	0.034% € 1.7m
Jane Pritchett Henderson	Independent Director	5.5yrs	US$385.84k	0.016% € 801.9k
Anat Lowenstein	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Heier	Member of Scientific Advisory Board	no data	sin datos	sin datos
Peter Kaiser	Member of Scientific Advisory Board	no data	sin datos	sin datos
Adnan Tufail	Member of Scientific Advisory Board	no data	sin datos	sin datos

4.6yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de O2T se considera experimentada (4.6 años de antigüedad promedio).

This company listing is no longer active

IVERIC bio Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Independent Director recently bought €231k worth of stock

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Recent updates

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

Independent Director recently bought €231k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

IVERIC Bio, Inc. Provides Updates on Clinical Trails

IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad